2016
DOI: 10.1038/aps.2016.114
|View full text |Cite
|
Sign up to set email alerts
|

Dose-biomarker-response modeling of the anticancer effect of ethaselen in a human non-small cell lung cancer xenograft mouse model

Abstract: Thioredoxin reductase (TrxR) is a component of several redox-sensitive signaling cascades that mediate important biological processes such as cell survival, maturation, growth, migration and inhibition of apoptosis. The expression levels of TrxR1 in some human carcinoma cell lines are nearly 10 times higher than those in normal cells. Ethaselen is a novel antitumor candidate that exerts potent inhibition on non-small cell lung cancer (NSCLC) by targeting TrxR. In this study we explored the relationship between… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
8
0
1

Year Published

2018
2018
2023
2023

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 16 publications
(9 citation statements)
references
References 40 publications
(60 reference statements)
0
8
0
1
Order By: Relevance
“…After the inoculation of lung cancer cell, A549 from the left ventricle (17), severe systemic failure, shortness of breath and a 20% weight loss in nude mice indicate that the mice have had cachexia. Nude mice were injected intraperitoneally with 50mg/kg of 1% thiopental sodium for nude mice (18) (Shanghai Xiyuan Biotechnology Co. Ltd., article number: XY-EP-T1200000).…”
Section: Animal Imaging Testmentioning
confidence: 99%
“…After the inoculation of lung cancer cell, A549 from the left ventricle (17), severe systemic failure, shortness of breath and a 20% weight loss in nude mice indicate that the mice have had cachexia. Nude mice were injected intraperitoneally with 50mg/kg of 1% thiopental sodium for nude mice (18) (Shanghai Xiyuan Biotechnology Co. Ltd., article number: XY-EP-T1200000).…”
Section: Animal Imaging Testmentioning
confidence: 99%
“…Besides, ethaselen, an ebselen derivative, is in the recruiting phase of a clinical trial to treat lung cancer. The compound has been effective in a pre-clinical trial in human non-small cell lung cancer models (Ye et al 2017 ; Zheng et al 2017b , 2019b ). In short, though ebselen has not been approved to treat a specific disease, its safety in humans has been an indication that organoselenium compounds can be promising therapeutic agents.…”
Section: Introductionmentioning
confidence: 99%
“…These observations have been confirmed in different tumor cell lines including HeLa (human cervical cancer), BGC823 (human stomach adenocarcinoma), HL60 and K562 (human leukemia), A549 (human lung cancer), LoVo (human colon cancer), Bel-7402 (human epithelial hepatoma), Tca8113 (human tongue cancer), and KB (human nasopharyngeal epidermal carcinoma) cells, as well as in a human non-small-cell lung cancer xenograft mouse model. 30 Moreover, combination of BBSKE with sodium selenite in non-small-cell lung cancer cells 31 or with sunitinib 32 in colorectal cancer showed synergistic effects, resulting in a promising new strategy for cancer therapy. In addition, this derivative is able to reverse cisplatin resistance in drug-resistant K562 cells.…”
Section: 2-selenazolesmentioning
confidence: 99%